Illumina, Inc. Expands Services Agreement With GlaxoSmithKline To Include Infinium(TM) Genotyping With HumanHap550 BeadChips For Large-Scale Disease Association Studies

SAN DIEGO--(BUSINESS WIRE)--Aug. 2, 2006--Illumina, Inc. (NASDAQ:ILMN) announced today that it has expanded the scope of its multi-year, genotyping services agreement with GlaxoSmithKline (GSK). Under the terms of the new agreement, Illumina will begin to use Sentrix(R) HumanHap550 BeadChips for a series of whole-genome association studies for GSK. The first such study involves genotyping a collection of 2,000 case and control DNA samples provided by GSK for a specific disease, detail for which was not provided.

Back to news